MONT-SAINT-GUIBERT, Belgium, March 17, 2025 (GLOBE NEWSWIRE) -- EsoBiotec SA, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, today ...
MONT-SAINT-GUIBERT, Belgium, Dec. 11, 2024 (GLOBE NEWSWIRE) -- EsoBiotec SA, a biotechnology company empowering cells in vivo to fight cancer, today announced the launch of an Investigator-Initiated ...
Poster talk will present safety and efficacy data for ENaBL-T, a lentiviral vector for in vivo engineering of BCMA CAR T cells, which supported the first in vivo BCMA CAR-T cell therapy clinical trial ...
British drug major AstraZeneca said on Monday it has entered into a definitive agreement to acquire EsoBiotec, a Belgian biotech company, for up to $1 billion on a cash and debt-free basis. The ...
(RTTNews) - British drug major AstraZeneca Plc (AZN, AZN.L) announced Monday that it has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company, for a total consideration of ...
(MENAFN- GlobeNewsWire - Nasdaq) Acquisition includes EsoBiotec's world-leading in vivo delivery platform with potential to transform cell therapy MONT-SAINT-GUIBERT, Belgium, March 17, 2025 (GLOBE ...
AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback